 |
Circulating nucleic acids in serum and plasma : CNAPS IX / edited by Peter B. Gahan, Michael Fleischhacker, Bernd Schmidt. -- Switzerland : Springer International Publishing, 2016. – (58.17425083/C578) |
Contents
Part I
Nucleic Acids in Oncology - Prognosis, Treatments Screening and
Metastases
1
Circulating Cell-Free miR-373, miR-200a, miR-200b and miR-200c in
Patients with Epithelial Ovarian Cancer
2
Cell-Free miRNA-141 and miRNA-205 as Prostate Cancer Biomarkers
3
Clinical Utility of Circulating Tumor DNA for Molecular Assessment and
Precision Medicine in Pancreatic Cancer
4 An
Enquiry Concerning the Characteristics of Cell-Free DNA Released by Cultured
Cancer Cells
5
Detection of p53 Mutations in Circulating DNA of Transplanted
Hepatocellular Carcinoma Patients as a Biomarker of Tumor Recurrence
6
Unbiased Detection of Somatic Copy Number Aberrations in cfDNA of Lung
Cancer Cases and High-Risk Controls with Low Coverage Whole Genome Sequencing
7
Liquid Profiling in Lung Cancer - Quantification of Extracellular miRNAs
in Bronchial Lavage
8
Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients
Suffering from Colon Cancer by COLD-PCR HRM
9
Non-dividing Cell Virtosomes Affect In Vitro and In Vivo Turnout Call
Replication
10
Features of Circulating DNA Fragmentation in Blood of Healthy Females
and Breast Cancer Patients
11
Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the
Management of Cancer Patients
Part II
CNAPS in Foetal Medicine
12
Characterization of Human Pregnancy Specific Glycoprotein (PSG) Gene
Copy Number Variations in Pre-eclampsia Patients
13
Non-invasive Prenatal Diagnosis of Feto-Maternal Platelet
Incompatibility by Cold High Resolution Melting Analysis
14
Implementing Non-Invasive Prenatal Diagnosis (NIPD) in a National Health
Service Laboratory; From Dominant to Recessive Disorders
Part III
Biology of CNAPS
15
Comparative Analysis of Harmful Physical Factors Effect on the Cell
Genome
16
Heterochromatic Tandem Repeats in the Extracellular DNA
17 A
Historical and Evolutionary Perspective on Circulating Nucleic Acids and
Extracellular Vesicles: Circulating Nucleic Acids as Homeostatic Genetic
Entities
18
Comparison of MicroRNA Content in Plasma and Urine Indicates the
Existence of a Transrenal Passage of Selected MicroRNAs
19 A
Quantitative Assessment of Cell-Free DNA Utilizing Several Housekeeping Genes:
Measurements from Four Different Cell Lines
20
Oligodeoxynucleotide Analogues of Circulating DNA Inhibit dsRNA-Induced
Immune Response at the Early Stages of Signal Transduction Cascade in a Cell
Type-Dependent Manner
21
GC-Rich DNA Fragments and Oxidized Cell-Free DNA Have Different Effects
on NF-kB and NRF2 Signaling in MSC
22
Evaluation of the State of Transplanted Liver Health by Monitoring of
Organ-Specific Genomic Marker in Circulating DNA from Receptor
23
Vesicular and Extra-Vesicular RNAs of Human Blood Plasma
24
Artificial Analogues of Circulating Box C/D RNAs Induce Strong Innate
Immune Response and MicroRNA Activation in Human Adenocarcinoma Cells
25
Multiple Ways of cfDNA Reception and Following ROS Production in
Endothelial Cells
26
Protein Content of Circulating Nucleoprotein Complexes
Part IV
Methodology
27
Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour
DNA
28
mFast-SeqS as a Monitoring and Pre-screening Tool for Tumor-Specific
Aneuploidy in Plasma DNA
29
Methodological Variables in the Analysis of Cell-Free DNA
30
Novel Technology for Enrichment of Biomolecules from Cell-Free Body
Fluids and Subsequent DNA Sizing
31 A
Rapid and Sensitive Method for Detection of the T790M Mutation of EGFR in
Plasma DNA
32
Evaluation of Different Blood Collection Tubes and Blood Storage
Conditions for the Preservation and Stability of Cell-Free Circulating DNA for
the Analysis of the Methylated mSEPT9 Colorectal Cancer Screening
Marker
33
Purification of Circulating Cell-Free DNA from Plasma and Urine Using
the Automated Large-Volume Extraction on the QIAsymphony® SP Instrument
34
Detection and Quantification of KIT Mutations in ctDNA by Plasma
Safe-SeqS
Part V
Ethics
35
Lost in Translation? Ethical Challenges of Implementing a New Diagnostic
Procedure
Part VI
Round-Table
36
Academia Meets Industry
Index
